Astronauts commonly reported acute and chronic pain during and after spaceflight, particularly in the lumbar spine. During and after spaceflight, astronauts experience lower back pain (LBP ...

According to the Global Burden of Disease Study, low back pain affects nearly 80% of people at some point in their lives.

Cebranopadol (GRT-6005) is under development for the treatment of acute pain, chronic low back pain, chronic neuropathic pain and opioid addiction. It is an orally administered analgesic agent that ...

And for many people, back pain can last a long time. A systematic review published in 2022 in the Journal of Pain found that ...

In conclusion, the study demonstrates the potential of brain biomarkers like CME and PAF to revolutionize pain management. By ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

In an international effort, researchers at Western, the University of Maryland School of Dentistry (UMSOD) and Neuroscience Research Australia (NeuRA) uncovered how specific patterns in brain activity ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

“Understanding who is at risk of developing chronic pain at the ... in clinical populations (jaw and low back pain) to predict who will transition from acute to chronic pain,” Schabrun reported.

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. The rising prevalence of chronic pain drives market growth by ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...